Reed Smith’s international arbitration practice is premised on three strands: specific industries such as life sciences, certain “specialisms” (specific types of arbitrations regardless of industry, such as investment treaty arbitration), and specific geographic regions in which our lawyers are especially well-suited to advise our clients.

This issue of our newsletter focuses on the highly topical and critical life sciences sector, one of our firm’s core industry focus areas. Recognized for its “stand out focus” on the life sciences industry (The Legal 500 USA 2020), our firm represents companies in the pharmaceutical, medical device, biotechnology, diagnostic and animal health sectors. Our international arbitration lawyers who concentrate in these fields have deep knowledge of the industry.

In this issue, lawyers from offices across our global network – including New York, Paris, London, Hong Kong, Singapore and Frankfurt – examine why arbitration is increasingly important to industry participants, and explore ways in which clients, be they large global companies, start-up enterprises, investors seeking opportunities, or trade organizations, can benefit from the protection afforded by both commercial arbitration and investment treaty arbitration.

We hope you enjoy reading this edition, and as always, we welcome your feedback.

View the newsletter online, or by downloading the PDF below.